LabNow Vice President Joe Skraba to present at Medtech's In3

June 12, 2005
Joe Skraba, VP of Business Development at LabNow will be presenting information on the LabNow Analyzer and BioChip System at Investment In Innovation (In3). The system is capable of performing rapid, low cost cellular and chemical assays at the point of care. The company, headquartered in Austin, Texas, has an exclusive, world-wide license for all applications of the novel, platform lab-on-a-chip sensor technology from The University of Texas at Austin. The technology has the capability to automate complex fluid analysis quickly, accurately and at lower cost than current methods. The microfluidics sensor technology has broad uses in medical, homeland security, environmental chemistry and process engineering applications. Mr. Skraba will be highlighting advances made by the company in HIV/AIDS monitoring and Cardiac Risk factor detection.

Technology Description
LabNow's initial focus is on point-of-care testing markets for in vitro diagnostic applications. In collaboration between UT and Massachusetts General Hospital (MGH) a prototype test system was developed and evaluated for rapid analysis of key blood measurements in HIV/AIDS patients. This measurement, CD4 lymphocyte count, is a key indicator of disease progression and is used to determine whether drug treatment is initiated or modified. The prototype CD4 test has been shown to statistically correlate with the current gold standard test conducted on state-of-the-art flow cytometry equipment.
The LabNow CD4 System has the ability to revolutionize the monitoring of treatment for HIV/AIDS patients. The test is conducted in a disposable microfluidics biochip in conjunction with a portable analyzer. The LabNow CD4 BioChip could be used in developed healthcare markets or in resource scarce countries. This system is being designed to have significant advantages over current measurement methods.
http://www.labnow.com

About In3

This two-day event will highlight emerging technologies being developed by more than 50 small, mostly privately-held medical technology companies seeking strategic partners and/or investment. The meeting will draw an attendance of over 350 senior executives from the investment community and major medical technology, biopharmaceutical, biotech, and other companies.

Back to News